Last updated: March 11, 2021

CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD²) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy.

Banner for CTD squared program. Links to CTD squared program page

News & Publications

View In the News Page

Tang et al. (2021) STAR Protocols. CC BY-NC-ND 4.0

CTD²

September 08, 2021

A time-resolved fluorescence resonance energy transfer screening assay for discovery of protein-protein interaction modulators

Protein-protein interactions (PPIs) have emerged as promising yet challenging therapeutic targets. A robust bioassay is required for rapid PPI modulator discovery. Here, we present a time-resolved Förster's (fluorescence) resonance energy transfer assay protocol for PPI modulator screening in a...

Dai et al. (2021) Cell Rep. CC BY-NC-ND 4.0

CTD²

July 27, 2021

SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization

Metastasis is a complex and poorly understood process. In pancreatic cancer, loss of the transforming growth factor (TGF)-β/BMP effector SMAD4 is correlated with changes in altered histopathological transitions, metastatic disease, and poor prognosis. In this study, we use isogenic cancer cell...

Su et al. (2021). Cell Rep Metods. CC BY-NC-ND 4.0

CTD²

July 23, 2021

Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis

Identifying biomarkers to predict the clinical outcomes of individual patients is a fundamental problem in clinical oncology. Multiple single-gene biomarkers have already been identified and used in clinics. However, multiple oncogenes or tumor-suppressor genes are involved during the process of...

Yang et al. (2021) Bioorg Med Chem. CC BY-NC-ND 4.0

CTD²

July 22, 2021

Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer

The transcription master regulator MYC plays an essential role in regulating major cellular programs and is a well-established therapeutic target in cancer. However, MYC targeting for drug discovery is challenging. New therapeutic approaches to control MYC-dependent malignancy are urgently...

Mohanty et al. (2021) Cell Reports Medicine. CC BY-NC-ND 4.0

CTD²

July 20, 2021

Uncoupling of gene expression from copy number presents therapeutic opportunities in aneuploid cancers

Uncoupling of mRNA expression from copy number (UECN) might be a strategy for cancer cells to a tolerate high degree of aneuploidy. To test the extent and role of UECN across cancers, we perform integrative multiomic analysis of The Cancer Genome Atlas (TCGA) dataset, encompassing ∼5,000...